undamentalytics Newsletter
Sign in

Vivos Therapeutics, Inc. (VVOS) stock

Add to watchlist

Add holding +

NASDAQ: VVOS Nasdaq Health Care Equipment Next results ~November 16, 2026

B Fundamentals grade

Vivos Therapeutics, Inc. is a US-listed company in the health care equipment industry. Its financial year ends in December.

Stock price today

Loading chart…

Third-party market data · may be delayed

Fair value per share

Under review: every model's value for Vivos Therapeutics, Inc. is far from the share price, which usually points to a data problem (a merger, a share-count change, a one-off) rather than a bargain or a bubble.

Price vs value

Under review: free cash flow after stock pay is not positive. We'll show the comparison once resolved.

Vivos Therapeutics, Inc. valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders1 buying, 0 selling2 purchases and 0 sales by directors and officers, last 12 monthsInsider trades
  • Funds5 adding, 8 cuttingOf 1 active managers that changed their stake, 0 added; quarter to June 30, 2026Fund buyers and sellers

Value diary

Our note on each quarter Vivos Therapeutics files

Where Vivos Therapeutics stands after its latest 10-Q

Revenue for the twelve months to June 2026 was $21m, up 45.2% on a year earlier, faster than the 33.8% growth a quarter earlier. That growth ranks 11 of 103 among the health care equipment companies we cover. Free-cash-flow margin rose to -91.0% from -108.8% a year earlier. Operating margin narrowed to -107.9% from -98.9%. Against its peers on growth, profitability, cash generation and balance sheet, it grades B. It passes 0 of our 5 financial-health checks.

Our model value for Vivos Therapeutics is under review, so past values are not shown until it is resolved.

Source: 10-Q filed August 14, 2026 on SEC EDGAR · Financials · Valuation

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Next results ~November 16, 2026 (estimated)

Vivos Therapeutics, Inc.'s trailing-twelve-month revenue grew 45.2% year on year, with a free-cash-flow margin of -91.0%. Where it stands out: days sales outstanding of 25 days ranks 9 of 118 health care equipment companies we cover.

Current signal Free cash flow diverging from earnings: TTM free cash flow fell 21.4% while net income fell 77.8%: a 56pp divergence.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Fast growth. Revenue grew 45.2% over the last 12 months, against a median of 9.1% for health care equipment companies we cover.
  • Growth speeding up. The growth rate is 11.4 points higher than a quarter earlier.

Things to watch

  • Loss-making. Operating margin is -107.9%: costs exceed revenue.
  • Margins narrowing. Operating margin is down 9.0 points on a year ago.
  • Burning cash. Free cash flow was -91.0% of revenue over the last 12 months.
  • Share dilution. Diluted shares rose 20.4% in a year.
  • Volatile shares. Over the past year the shares showed annualised volatility of 95% and a beta of 1.4 against the S&P 500.
  • Short interest rising. Shares sold short rose 45% in a month to 7.6% of tradable shares.

Latest results: FY2026 Q2

Filed August 14, 2026
Earnings per share
-$0.31 against an average estimate of -$0.39: beat by 20.5%
Revenue
$5m, up 34.9% on a year earlier
Next report
November 16, 2026; average EPS estimate -$0.32

Vivos Therapeutics' figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day+1.8%
  • 1 week-14.1%
  • 1 month-27.7%
  • This year-94.7%
  • 1 year-95.6%
  • 5 years-99.9%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$20.9M
Operating margin
-107.9%
Net margin
-121.8%
EPS (TTM, diluted)
$-1.83

Growth

Revenue growth
+45.2%
Change in growth rate
+11.4 pts

Cash

Free cash flow (TTM)
-$19M
FCF margin
-91.0%
Stock pay % of revenue
1.9%

Earnings

Last results
April 15, 2026

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Announcement
  2. Deal
  3. Agreement
  4. Agreement
  5. Announcement
  6. Announcement
  7. Leadership
  8. Agreement

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Vivos Therapeutics, Inc. valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: free cash flow after stock pay is not positive.

The inputs used by the models below have passed source checks. Individual model values are available below and in the interactive valuator. Their differences are shown explicitly; the platform combined value and recommendation remain withheld.

Valuation models

We value Vivos Therapeutics, Inc. as an operating company, with every model that fits that kind of business. Cost of equity 10.2%: the 10-year Treasury yield (4.9%) plus a beta of 1.16 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Growth cash-flow model Revenue for this year and next from analysts' consensus, then growth fading to 2.5%; the operating margin moving to profitable peers'; investment needed per dollar of growth from peers; reduced by a failure probability. For young or fast-growing companies. The starting margin is normalized to between -100% and 60%; net margin is a proxy when operating income is not tagged. Uses analysts' consensus estimates (third-party data), not our forecasts. — Does not apply: the projected cash flows don't support a positive value
Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. — Does not apply: This model is withheld pending its input or assumption review.
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. — Does not apply: This model is withheld pending its input or assumption review.
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. — Does not apply: This model is withheld pending its input or assumption review.
Forward price-to-sales vs peers Next year's consensus sales per share times peers' typical forward price-to-sales; only when earnings are negative. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$4.2 ~$3.3–$11 Left out: out of range vs price (38.52x)
Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. — Does not apply: This model is withheld pending its input or assumption review.
Combined value Individual source-checked model scenarios are available. The platform combined value and recommendation remain withheld. — Combined value withheld. Review the individual models and their assumptions.

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Vivos Therapeutics, Inc. with Health Care Equipment in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Valuation multiples over time Market data may be delayed

At fiscal year end 202020212022202320242025Now
Share price$147.75$56.25$10.05$12.44$4.29$2.03$0.11
Market value$608m$382m$74m$121m$43m$21m$2m
+ Net debt (− = net cash)−$17m−$23m−$4m−$443000−$5m$17m$14m
Enterprise value$592m$359m$70m$121m$38m$38m$15m
Multiples
Price / sales 46.6x22.6x4.6x8.8x2.9x1.2x0.1x
Price / earnings ———————
Price / free cash flow ———————
EV / EBITDA ———————

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

30 /100

Weak moat

How hard Vivos Therapeutics's competitive advantage looks for rivals to wear away, judged from 6 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

  • Returns on capital 0 / 20

    Cash operating profit has been a median -75.7% of total assets over 5 years.

  • Pricing power 14 / 20

    Gross margin has been a median 61.1%, moving by 7.8 percentage points (standard deviation) across 6 years.

  • Durability 10 / 20

    Operating margin has been a median -107.4%; its worst year was -158.1%.

  • Cash conversion 0 / 20

    Free cash flow was positive in 0 of 6 years, at a median -98.4% of revenue.

AI disruption exposure: Low. In this industry, the business rests on physical assets, regulated networks or products AI itself depends on.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Next results: November 16, 2026, after the close. Analysts expect revenue of $5m and EPS of −$0.32 (range −$0.54 to −$0.12) for the quarter.

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current −$1.40 +33% $22m +25%
Next −$0.82 +41% $34m +56%

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is +0.3% on 90 days ago. In the last 30 days, 1 analyst raised Vivos Therapeutics, Inc.'s forecast and 0 cut it.

Consensus EPS forecast Vivos Therapeutics, Inc., last 90 days
−$1.50 −$1.00 −$0.50 $0.00 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: −$1.39 Current fiscal year, 60 days ago: −$1.34 Current fiscal year, 30 days ago: −$1.34 Current fiscal year, 7 days ago: −$1.34 Current fiscal year, Now: −$1.40 −$1.40 Next fiscal year, 90 days ago: −$0.35 Next fiscal year, 60 days ago: −$0.84 Next fiscal year, 30 days ago: −$0.79 Next fiscal year, 7 days ago: −$0.79 Next fiscal year, Now: −$0.82 −$0.82

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago −$1.39−$0.35
60 days ago −$1.34−$0.84
30 days ago −$1.34−$0.79
7 days ago −$1.34−$0.79
Now −$1.40−$0.82

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 −$0.39 −$0.31 +20.5%
Mar 2026 −$0.45 −$0.52 −14.7%
Dec 2025 −$0.48 −$0.58 −20.0%
Sept 2025 −$0.51 −$0.49 +3.9%

Adjusted EPS as companies report it, against the average analyst estimate.

Analyst recommendations

2 analysts, Oct 2026
Buy150%
Hold150%
Sell00%

Monthly trend

  1. Oct 2026112
  2. Sep 2026213
  3. Aug 2026213

Counts of recommendations published by analysts covering Vivos Therapeutics, Inc., by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
7.6%
of tradable shares
Days to cover
0.45
at average volume
Short interest, 1 month
+45%
to October 15, 2026
Held by institutions
4%
of shares
Held by insiders
11.3%
of shares
Employees
268
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

Recent prices are available. Older price history and the statistics that need it are being loaded in the background.

Return and risk by year

Calendar year 202120222023202420252026 to date
Return
VVOS−62%−82%+24%−66%−53%−95%
Industry peers (median)−7%−37%−9%−19%−16%−13%
S&P 500+29%−18%+26%+25%+18%+11%
Months that ended higher
VVOS33%42%42%42%17%0%
S&P 50075%42%67%75%75%46%
Largest fall from a high during the year
VVOS−77%−91%−94%−84%−72%−96%
S&P 500−5%−25%−10%−8%−19%−9%

Worst fall since December 11, 2020: 100% from April 6, 2021 to November 2, 2026. Getting back needed a 223743% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$0.11 – $2.59
From 52-week high
−95.8%
vs 50-day average
−33.1%
vs 200-day average
−85.3%
Volatility (1 year)
95%
Beta vs S&P 500
1.37

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
3 up, 9 down
typical move ±10.8%
After a week
3 up, 9 down
typical move ±17.9%
After a month
4 up, 8 down
typical move ±26.3%
Results releasedNext dayS&P 500 next day5 days21 days
April 15, 2026 −19.3% +1.0% −23.7% −48.9%
November 19, 2025 −14.2% −1.1% −9.3% −20.2%
August 20, 2025 +7.7% −0.7% +7.6% −19.4%
May 15, 2025 −16.4% +1.1% −31.2% −26.6%
March 31, 2025 −15.4% +1.0% −19.0% −8.7%
November 14, 2024 −9.0% −1.9% −5.4% +58.7%
August 15, 2024 −1.7% +1.9% +13.9% +24.5%
May 15, 2024 −9.2% +1.0% −14.5% −9.6%
March 29, 2024 −30.2% −0.2% −37.7% −46.4%
August 16, 2023 −2.1% −1.5% −19.9% −24.8%
June 8, 2023 +1.7% +0.8% +32.8% +22.4%
March 30, 2023 +3.3% +2.0% −0.3% +5.2%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Vivos Therapeutics, Inc. in five measures

Fundamentals grade B
Growth Profitability Cash Balance sheet

Growth, profitability, cash generation and balance sheet are percentiles against the companies we cover in the same industry, from SEC filings (100 = best). Value compares the share price with our modelled value range (50 = at our base value; higher = cheaper). A description of reported data and our model — not a quality score or advice.

Fundamentals

Revenue (TTM) Vivos Therapeutics, Inc.
$12M $14M $16M $18M $20M $22M FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue (TTM), FY23 Q3: $14.5M Revenue (TTM), FY23 Q4: $13.8M Revenue (TTM), FY24 Q1: $13.4M Revenue (TTM), FY24 Q2: $14M Revenue (TTM), FY24 Q3: $14.6M Revenue (TTM), FY24 Q4: $15M Revenue (TTM), FY25 Q1: $14.6M Revenue (TTM), FY25 Q2: $14.4M Revenue (TTM), FY25 Q3: $17.3M Revenue (TTM), FY25 Q4: $17.4M Revenue (TTM), FY26 Q1: $19.6M Revenue (TTM), FY26 Q2: $20.9M $20.9M

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue (TTM)
FY23 Q3 $14.5M
FY23 Q4 $13.8M
FY24 Q1 $13.4M
FY24 Q2 $14M
FY24 Q3 $14.6M
FY24 Q4 $15M
FY25 Q1 $14.6M
FY25 Q2 $14.4M
FY25 Q3 $17.3M
FY25 Q4 $17.4M
FY26 Q1 $19.6M
FY26 Q2 $20.9M
Revenue growth, TTM YoY Vivos Therapeutics, Inc.
-20% 0% 20% 40% 60% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue growth, TTM YoY, FY23 Q3: -11.9% Revenue growth, TTM YoY, FY23 Q4: -13.9% Revenue growth, TTM YoY, FY24 Q1: -17.7% Revenue growth, TTM YoY, FY24 Q2: -9.2% Revenue growth, TTM YoY, FY24 Q3: 0.5% Revenue growth, TTM YoY, FY24 Q4: 8.9% Revenue growth, TTM YoY, FY25 Q1: 9.5% Revenue growth, TTM YoY, FY25 Q2: 2.7% Revenue growth, TTM YoY, FY25 Q3: 18.8% Revenue growth, TTM YoY, FY25 Q4: 16.0% Revenue growth, TTM YoY, FY26 Q1: 33.8% Revenue growth, TTM YoY, FY26 Q2: 45.2% 45.2%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue growth, TTM YoY
FY23 Q3 -11.9%
FY23 Q4 -13.9%
FY24 Q1 -17.7%
FY24 Q2 -9.2%
FY24 Q3 0.5%
FY24 Q4 8.9%
FY25 Q1 9.5%
FY25 Q2 2.7%
FY25 Q3 18.8%
FY25 Q4 16.0%
FY26 Q1 33.8%
FY26 Q2 45.2%
Operating margin (TTM) Vivos Therapeutics, Inc.
-150% -100% -50% 0% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Operating margin (TTM), FY23 Q3: -132.6% Operating margin (TTM), FY23 Q4: -125.3% Operating margin (TTM), FY24 Q1: -120.3% Operating margin (TTM), FY24 Q2: -96.2% Operating margin (TTM), FY24 Q3: -85.7% Operating margin (TTM), FY24 Q4: -74.3% Operating margin (TTM), FY25 Q1: -77.3% Operating margin (TTM), FY25 Q2: -98.9% Operating margin (TTM), FY25 Q3: -94.3% Operating margin (TTM), FY25 Q4: -114.1% Operating margin (TTM), FY26 Q1: -115.5% Operating margin (TTM), FY26 Q2: -107.9% -107.9%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Operating margin (TTM)
FY23 Q3 -132.6%
FY23 Q4 -125.3%
FY24 Q1 -120.3%
FY24 Q2 -96.2%
FY24 Q3 -85.7%
FY24 Q4 -74.3%
FY25 Q1 -77.3%
FY25 Q2 -98.9%
FY25 Q3 -94.3%
FY25 Q4 -114.1%
FY26 Q1 -115.5%
FY26 Q2 -107.9%
FCF margin (TTM) Vivos Therapeutics, Inc.
-150% -100% -50% 0% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 FCF margin (TTM), FY23 Q3: -89.9% FCF margin (TTM), FY23 Q4: -92.4% FCF margin (TTM), FY24 Q1: -87.1% FCF margin (TTM), FY24 Q2: -83.0% FCF margin (TTM), FY24 Q3: -89.6% FCF margin (TTM), FY24 Q4: -88.2% FCF margin (TTM), FY25 Q1: -99.2% FCF margin (TTM), FY25 Q2: -108.8% FCF margin (TTM), FY25 Q3: -88.7% FCF margin (TTM), FY25 Q4: -100.9% FCF margin (TTM), FY26 Q1: -100.7% FCF margin (TTM), FY26 Q2: -91.0% -91.0%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period FCF margin (TTM)
FY23 Q3 -89.9%
FY23 Q4 -92.4%
FY24 Q1 -87.1%
FY24 Q2 -83.0%
FY24 Q3 -89.6%
FY24 Q4 -88.2%
FY25 Q1 -99.2%
FY25 Q2 -108.8%
FY25 Q3 -88.7%
FY25 Q4 -100.9%
FY26 Q1 -100.7%
FY26 Q2 -91.0%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-K/A, 10-Q, 10-Q/A. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2019 Dec 2019 2020 Dec 2020 2021 Dec 2021 2022 Dec 2022 2023 Dec 2023 2024 Dec 2024 2025 Dec 2025 LTM Jun 2026
Income
Revenue 11 13 17 16 14 15 17 21
Gross profit 9 10 13 10 8 9 11 13
EBITDA −10 −11 −20 −24 −17 −11 −19 −21
Operating income −11 −12 −20 −25 −17 −11 −20 −23
Net income −11 −12 −20 −24 −14 −11 −21 −25
Diluted EPS −$2.97 −$0.17 −$0.12 −$3.24 −$1.39 −$1.11 −$2.07 −$1.83
Growth (year on year)
Revenue — +14.7% +29.2% −5.1% −13.9% +8.9% +16.0% +45.2%
Margins
Gross margin 76.0% 79.7% 74.6% 62.5% 59.9% 60.0% 60.4% 61.9%
EBITDA margin −86.2% −86.7% −116.4% −152.0% −120.8% −70.5% −106.5% −99.4%
Operating margin −92.8% −92.1% −120.7% −156.2% −125.3% −74.3% −114.1% −107.9%
Net margin −94.4% −92.3% −120.2% −148.8% −98.4% −74.1% −121.4% −121.8%
Free-cash-flow margin −48.4% −44.4% −107.4% −128.0% −92.4% −88.2% −100.9% −91.0%
Cash flow
Cash from operations −5 −6 −16 −20 −12 −13 −15 −17
Capital spending 0 0 2 1 1 1 2 2
Free cash flow −6 −6 −18 −21 −13 −13 −18 −19
Stock-based pay 2 2 3 2 1 1 1 0
Free cash flow after stock pay −8 −8 −21 −23 −14 −14 −18 −19
Balance sheet
Cash 0 18 24 4 2 6 2 2
Total debt 4 1 1 — 1 1 19 16
Net debt (negative = net cash) 3 −17 −23 −4 −0 −5 17 14
Diluted shares 4m 4m 7m 7m 10m 10m 10m 14m

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

0 of 5 checks passed · June 30, 2026
What it owns · $24m
Short-term assets $4mLonger-term assets $20m
What it owes, and who funded it · $28m
Short-term liabilities $20mLonger-term liabilities $8mShareholders' equity $-4m
  • Short-term assets cover short-term liabilities $4m of assets due within a year against $20m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $4m short-term assets against $8m of longer-dated liabilities.
  • More cash than debt $2m of cash against $8m of debt.
  • Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
  • Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
  • A year's operating cash flow covers at least 20% of debt −$17m of operating cash flow against $8m of debt.
  • Operating profit covers interest at least five times over Operating income of −$23m against $4m of interest.

From Vivos Therapeutics, Inc.'s latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

Days sales outstanding
25 days
receivables vs revenue

Competitors: side by side with peers

Closest by revenue in health care equipment
Last 12 months unless stated VVOS NEPH ZJYL SNOA BDMD SRTS Median
Revenue, last 12 months $21m $21m $21m $22m $23m $18m $99m
Revenue growth, last 12 months 45.2% 24.2% −12.0% 47.0% −39.2% −53.4% 9.2%
Revenue growth, 3-year average 10.6% 19.3% — 19.9% — −16.5% 13.5%
Revenue growth, latest quarter 34.9% 36.2% — 59.6% — −68.7% 10.2%
Gross margin 61.9% 61.3% 29.2% 38.9% 83.8% 36.4% 61.2%
Operating margin −107.9% 7.9% 2.9% −6.4% −113.7% −75.7% −8.5%
Operating margin, 3-year average −101.0% 2.0% — −22.4% — −18.6% −17.9%
Net margin −121.8% 8.4% 5.8% −10.3% −121.0% −88.5% −12.0%
Cash from operations / revenue −82.0% −3.4% 14.0% −11.7% −6.0% −38.8% −1.9%
Free-cash-flow margin −91.0% −4.0% −18.0% −12.1% −6.2% −39.8% −3.9%
Free-cash-flow margin, 3-year average −94.3% −0.1% — −15.2% — −11.2% −7.0%
Stock pay / revenue 1.9% 1.3% — 1.2% 77.5% 1.2% 6.1%
Change in share count 20.4% 4.0% 0.0% 55.4% 27.3% 0.2% 4.0%

Median of all 134 companies we cover in health care equipment. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Peer comparison

134 health care equipment companies
Measure Company Peer median Rank
Revenue growth Growth 45.2% 9.1% 15 of 129
Change in growth rate Growth +11.4pp -0.6pp 13 of 129
Gross margin Profitability 61.9% 61.9% 62 of 123
Operating margin Profitability -107.9% -8.3% 103 of 132
Net margin Profitability -121.8% -12.0% 106 of 133
Free-cash-flow margin Cash generation -91.0% -3.4% 102 of 128
Stock pay as % of revenue Cash generation 1.9% 6.1% 29 of 123
Long-term debt as % of assets Balance sheet 1.5% 24.2% 13 of 87
Days sales outstanding Balance sheet 25 days 57 days 9 of 118

Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).

Where the revenue comes from

Fiscal year to December 31, 2025
Products and services
Line of business Revenue YoY
Services $11M ▲ 53.1%
Products $6.5M ▼ 17.6%
Sleep Testing Services $6M ▲ 371.2%
Appliances $3.3M ▼ 41.5%
Tooth Positioners $3.2M ▲ 41.2%
Treatment Centers $2.2M —
Sponsorship Seminar Other $1.2M ▼ 37.0%
Billing Intelligence Services $686,000 ▼ 18.3%
VIP $491,000 ▼ 80.2%
Myofunctional Therapy Services $337,000 ▼ 44.7%

These categories overlap or exclude eliminations, so shares aren't shown.

From Vivos Therapeutics, Inc.'s 10-K filed April 15, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Who owns it

Funds buying and selling
Reported value
$242,880
Institutions reporting
22
Shares held vs prior quarter
▼ 70.9%
Positions opened / closed
2 / 4

Top buyers and sellers, Q2 2026: 5 institutions bought and 8 sold ; the biggest buyer was Iht Wealth Management, LLC (+36K shares) and the biggest seller Armistice Capital, LLC (−1.1M). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Geode Capital Management, LLC $38,632 85K 15.9% ▼ 11.0%
Iht Wealth Management, LLC $34,877 77K 14.4% ▲ 86.9%
Vanguard Capital Management LLC $27,586 61K 11.4% ▼ 77.8%
Commonwealth Equity Services, LLC $19,320 43K 8.0% 0.0%
B. Riley Wealth Advisors, Inc. $18,767 38K 7.7% 0.0%
UBS Group AG $17,815 39K 7.3% ▲ 254.5%
Centurion Wealth Management LLC $16,219 36K 6.7% 0.0%
Blackrock, Inc. $12,643 28K 5.2% 0.0%
State Street Corp $11,327 25K 4.7% 0.0%
Sequoia Financial Advisors, LLC $10,908 24K 4.5% 0.0%
Vanguard Fiduciary Trust Co $10,662 23K 4.4% ▼ 24.0%
Northern Trust Corp $9,442 21K 3.9% ▲ 66.1%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Vivos Therapeutics, Inc.'s complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart
Insider purchases History → $1.8M 2 trades by 1 insider, last 12 months Insider sales History → $0 0 trades by 0 insiders
Net ▲ $1.8M net buying
Insider Date Trade Shares Price Value
V-Co Investors 3 Llc 10% owner March 31, 2026 Buy 1,044,777 $1.34 $1.4M
V-Co Investors 3 Llc 10% owner March 31, 2026 Buy 308,848 $1.34 $413,856

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

Next expected around July 16, 2026 estimated from the company's past filing pattern, not announced

  • April 15, 2026
  • November 19, 2025
  • August 20, 2025
  • May 15, 2025
  • March 31, 2025
  • November 14, 2024

Recent SEC filings

Data status

When each part of this page on Vivos Therapeutics, Inc. was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Vivos Therapeutics, Inc. in brief

What does Vivos Therapeutics, Inc. do?
Vivos Therapeutics, Inc. is a US-listed company in the health care equipment industry. Its financial year ends in December.
What is Vivos Therapeutics, Inc.'s stock ticker?
Vivos Therapeutics, Inc. trades under the ticker VVOS on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Vivos Therapeutics, Inc.'s revenue, and how fast is it growing?
Over its most recent trailing twelve months, Vivos Therapeutics, Inc. reported revenue of $20.9M, 45.2% higher than a year earlier, according to its SEC filings.
What is Vivos Therapeutics, Inc.'s free cash flow?
Vivos Therapeutics, Inc.'s free-cash-flow margin is -91.0% of revenue over the trailing twelve months, ranking 102 of the 128 health care equipment companies we cover.
Who are Vivos Therapeutics, Inc.'s largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Geode Capital Management, LLC, Iht Wealth Management, LLC and Vanguard Capital Management LLC. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
What is Vivos Therapeutics, Inc.'s market cap?
On November 2, 2026, Vivos Therapeutics, Inc.'s market capitalisation was about $1.5M and net debt of $13.9M. Market figures come from third-party market data and may be delayed.
Who are Vivos Therapeutics, Inc.'s competitors?
In our Health Care Equipment peer group, the companies closest to Vivos Therapeutics, Inc. are Nephros Inc, Jin Medical International Ltd., Sonoma Pharmaceuticals, Inc., Baird Medical Investment Holdings Ltd and Sensus Healthcare, Inc. The side-by-side comparison below sets their revenue, margins and growth against Vivos Therapeutics, Inc.'s.
Are insiders buying or selling Vivos Therapeutics, Inc. stock?
Over the last 12 months, Vivos Therapeutics, Inc.'s directors and officers reported 2 open-market purchases and 0 sales on Form 4. The insider trading page charts every trade.
When is Vivos Therapeutics, Inc.'s next earnings date?
Around November 16, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Vivos Therapeutics, Inc. announces its own schedule.